389: Hims' Super Bowl fallout, and the FDA reverses course

What It Covers

Three major healthcare stories dominate: the FDA's reversal on Moderna's flu vaccine application amid political pressure from the Trump administration, Compass Pathways reporting positive Phase 3 psychedelic depression trial results, and Hims & Hers facing FDA scrutiny, an HHS-DOJ referral, and a 30% stock drop after launching a compounded semaglutide pill.

Key Questions Answered

• •FDA Political Vulnerability: The FDA's reversal on Moderna's flu vaccine—accepting the application within days of initial rejection—followed reports that President Trump directly expressed frustration to Moderna's leadership. Investors and analysts should treat FDA decisions under the current administration as potentially subject to political override, particularly on vaccine-related matters approaching the 2026 midterm elections.
• •Compass Pathways Depression Trial Benchmarks: Compass defined "clinically meaningful response" as a 25% reduction on the MADRS scale—lower than the 50% threshold used in comparable trials. Remission rates at six weeks reached only 6%, using a MADRS cutoff of under 12 rather than the standard under 10. Analysts evaluating psychedelic drug approvals should scrutinize endpoint definitions carefully before drawing efficacy conclusions.
• •Compounded GLP-1 Regulatory Risk: Hims & Hers used liposomal technology for its compounded oral semaglutide pill—a formulation the FDA previously proposed banning from compounding, though never finalized. Companies marketing compounded GLP-1 products should treat that unfinalized proposal as a live regulatory threat, particularly as FDA enforcement escalates beyond marketing violations toward the underlying compounding framework.
• •Telehealth Vertical Integration Model: Direct-to-consumer telehealth companies like Hims & Hers generate revenue by vertically integrating a management services organization, affiliated medical groups, and in-house pharmacies—capturing drug revenue, not just consultation fees. White-label infrastructure now allows new telehealth brands to launch in days by renting this structure, operating in regulatory gaps written before internet-era healthcare delivery existed.
• •Psychedelic Medicine Commercial Pathway: Compass Pathways' psilocybin drug requires patients to remain in treatment facilities for six to eight hours per session, creating significant insurance coverage and cost challenges. However, its less frequent dosing schedule compared to J&J's ketamine-derived Spravato—which already generates substantial revenue—positions it as a commercially viable option if FDA approves it, despite the high per-session healthcare system cost.